Integrating data from multidisciplinary Management of Malignant Pleural Mesothelioma: a cohort study.
Asbestos
Imaging
Mesothelioma
Multidisciplinary team
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
01 Jul 2021
01 Jul 2021
Historique:
received:
14
09
2020
accepted:
23
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
11
2021
Statut:
epublish
Résumé
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy that most commonly affects the pleural layers. MPM has a strong association with asbestos, mainly caused by exposure to its biopersistent fibers in at least 80% of cases. Individuals with a chronic exposure to asbestos might develop disease with a 20-40-year latency with few or no symptoms. Such has been the case in the Italian regions of Piedmont and Lombardy, where industrial production of materials laden with asbestos, mainly cements, has been responsible for the onset of a large epidemic. Since 2018, a multidisciplinary team at San Matteo hospital in Pavia has been collecting data on over 100 patients with MPM. The main goal of this project is to define and describe an integrated profile for each MPM case at diagnosis by using data mining and partition analysis. Here we bring together exhaustive epidemiologic, histologic and radiologic data of 88 MPM patients that came to our observation and draw correlations with predictive and prognostic significance. The median overall survival (OS) was 15.6 months. Most patients presented with pleural effusion, irrespective of disease stage. Quite unexpectedly, no statistically significant association was demonstrated between OS and TNM disease stage at diagnosis. Although average OS is similar in male and female patients, partition analysis of data underlined a significant differential hierarchy of predictor categories based on patient gender. In females with no smoking history, full chemotherapeutic regimens are associated with better outcomes. Moreover, concerning second line treatments, vinorelbine emerged as the most advantageous choice for female patients, whereas in the male subgroup no statistically significant difference resulted between gemcitabine and vinorelbine. A multidisciplinary approach to MPM is mandatory to define better therapeutic approaches, personalize the management and improve patient outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy that most commonly affects the pleural layers. MPM has a strong association with asbestos, mainly caused by exposure to its biopersistent fibers in at least 80% of cases. Individuals with a chronic exposure to asbestos might develop disease with a 20-40-year latency with few or no symptoms. Such has been the case in the Italian regions of Piedmont and Lombardy, where industrial production of materials laden with asbestos, mainly cements, has been responsible for the onset of a large epidemic. Since 2018, a multidisciplinary team at San Matteo hospital in Pavia has been collecting data on over 100 patients with MPM. The main goal of this project is to define and describe an integrated profile for each MPM case at diagnosis by using data mining and partition analysis.
METHODS
METHODS
Here we bring together exhaustive epidemiologic, histologic and radiologic data of 88 MPM patients that came to our observation and draw correlations with predictive and prognostic significance.
RESULTS
RESULTS
The median overall survival (OS) was 15.6 months. Most patients presented with pleural effusion, irrespective of disease stage. Quite unexpectedly, no statistically significant association was demonstrated between OS and TNM disease stage at diagnosis. Although average OS is similar in male and female patients, partition analysis of data underlined a significant differential hierarchy of predictor categories based on patient gender. In females with no smoking history, full chemotherapeutic regimens are associated with better outcomes. Moreover, concerning second line treatments, vinorelbine emerged as the most advantageous choice for female patients, whereas in the male subgroup no statistically significant difference resulted between gemcitabine and vinorelbine.
CONCLUSION
CONCLUSIONS
A multidisciplinary approach to MPM is mandatory to define better therapeutic approaches, personalize the management and improve patient outcomes.
Identifiants
pubmed: 34210265
doi: 10.1186/s12885-021-08532-x
pii: 10.1186/s12885-021-08532-x
pmc: PMC8252222
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
762Subventions
Organisme : Fondazione Regionale per la Ricerca Biomedica
ID : Plagencell project
Références
Eur Respir Rev. 2015 Mar;24(135):115-31
pubmed: 25726562
Acta Biomed. 2017 Aug 23;88(2):134-142
pubmed: 28845826
Eur Respir J. 2020 Jun 11;55(6):
pubmed: 32451346
F1000Res. 2018 Oct 22;7:
pubmed: 30410726
Transl Lung Cancer Res. 2018 Oct;7(5):543-549
pubmed: 30450292
Eur Respir J. 1996 Sep;9(9):1932-42
pubmed: 8880114
Bull World Health Organ. 2011 Oct 1;89(10):716-24, 724A-724C
pubmed: 22084509
PLoS One. 2015 Aug 14;10(8):e0135798
pubmed: 26274395
Iran J Radiol. 2012 Nov;9(4):209-11
pubmed: 23407863
Cancer Res. 1991 May 1;51(9):2263-7
pubmed: 2015590
Environ Res. 2020 Apr;183:108968
pubmed: 31812249
Cancers (Basel). 2020 May 07;12(5):
pubmed: 32392897
J Thorac Oncol. 2020 Jun;15(6):914-947
pubmed: 32179179
Occup Environ Med. 2018 Apr;75(4):254-262
pubmed: 29269563
Environ Int. 2015 Jan;74:191-9
pubmed: 25454236
Radiographics. 2004 Jan-Feb;24(1):105-19
pubmed: 14730040
In Vivo. 2018 Sep-Oct;32(5):1169-1174
pubmed: 30150440
Transl Lung Cancer Res. 2018 Oct;7(5):574-583
pubmed: 30450296
Pathology. 2013 Jan;45(1):44-8
pubmed: 23222247
Med Lav. 2016 Jul 26;107(4):307-14
pubmed: 27468090
Int J Environ Res Public Health. 2020 Dec 28;18(1):
pubmed: 33379304
Front Oncol. 2020 Jan 24;9:1519
pubmed: 32039010
Curr Treat Options Oncol. 2014 Dec;15(4):683-99
pubmed: 25266654
BMC Cancer. 2015 May 08;15:374
pubmed: 25952930
Transl Lung Cancer Res. 2020 Jun;9(3):934-943
pubmed: 32676359
Eur J Radiol. 2016 Sep;85(9):1594-600
pubmed: 27501894
Ann Cardiothorac Surg. 2012 Nov;1(4):491-6
pubmed: 23977542
Lung Cancer. 2015 Sep;89(3):223-31
pubmed: 26162564